IGF-1 LR3

IGF-1 LR3 research material, available in 0.1 mg and 1 mg vials. For in-vitro research only.

• The construct is an IGF-I sequence preceded by the first eleven residues of methionyl porcine growth hormone plus Val-Asn, with Glu3 of the human sequence replaced by arginine, and the cited work attributes its raised potency to changed interaction with the binding proteins rather than to the receptor. [1]
• In a cell line that does not secrete detectable binding proteins into the medium, the analogue was less potent than native IGF-I, which reverses the ordering seen in lines that do secrete them. [1]
• Recombinant IGFBP-3 suppressed proliferation stimulated by native IGF-I and by the analogue alike, but suppressed differentiation only when native IGF-I was the stimulus, separating a binding protein dependent effect from a binding protein independent one. [2] [3]
• Analysis of a vial obtained outside regulated supply identified the analogue carrying a hexahistidine tag at the C-terminus through a Leu-Glu linker, a purification tag normally removed or left only on material made for biochemical study. [4]

Compound

IGF-1 LR3

Purity

99.60% (HPLC)

Identity

Confirmed by MS

Appearance

White lyophilate

Presentation

0.1 mg · 1 mg

Catalog / lot

RV-0035 / RV-24-0035-1

For research use only. Not for human or veterinary use. Not a drug, food, cosmetic, or supplement.

Review the laboratory, lot identifier, and reported results in this document. Keep the lot identifier with your research records.